|1.||Shoenfeld, Yehuda: 44 articles (03/2015 - 04/2002)|
|2.||Shoenfeld, Y: 26 articles (12/2015 - 01/2000)|
|3.||Dalakas, Marinos C: 24 articles (02/2015 - 12/2002)|
|4.||Kaveri, Srini V: 20 articles (07/2015 - 01/2003)|
|5.||Bayry, Jagadeesh: 18 articles (07/2015 - 01/2003)|
|6.||Lazarus, Alan H: 18 articles (06/2015 - 05/2003)|
|7.||Burns, Jane C: 17 articles (05/2015 - 02/2003)|
|8.||Bazin, Renée: 15 articles (02/2014 - 10/2004)|
|9.||Nimmerjahn, Falk: 14 articles (10/2015 - 01/2007)|
|10.||Crow, Andrew R: 13 articles (06/2015 - 05/2003)|
10/01/1998 - "Most studies demonstrate beneficial results of IVIG treatment, especially on frequency and severity of infections in patients with advanced HIV disease. "
01/01/2004 - "Treatment with IVIG (seven trials, n = 262) in cases of subsequently proven infection did result in a statistically significant reduction in mortality [typical RR 0.55 (95% CI; 0.31, 0.98)In spite of different geographical locations of the studies, differences in the mortality in the control groups (range 0% - 43.8%), the use of different IVIG preparations, and different dosing regimens, there was no statistically significant between-study heterogeneity for the outcome of mortality in the two analyses. "
01/01/2014 - "In patients with active disease and concomitant infections, the response to IVIG treatment was a complete remission (n=9), partial remission (n=8), and no response (n=8). "
01/01/2002 - "The intravenous immunoglobulins has been proven beneficial in prophylaxis and treatment of infections in patients with primary and secondary immunodeficiency. "
06/01/1987 - "IVIG (0.025 g/kg) administered topically by the intranasal route to anesthetized cotton rats at the height of RSV infection effected a 10(2.2)-fold reduction in viral titers of pulmonary tissues and a complete clearance of detectable virus in 92% of the animals within 24 h. "
|2.||Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
08/01/1996 - "Of the 30 patients, 19 (63%) improved with IvIg treatments; nine out of 16 patients (56%) with chronic progressive CIDP, and 10 out of 14 patients (71%) with relapsing CIDP (differences were not statistically significant). "
06/01/1991 - "High-dose IVIG was a safe and effective adjunctive therapy for childhood CIDP in these four patients."
07/01/2015 - "This difference may help to balance the more frequent response to IVIg than to IVMP in patients with CIDP."
05/01/2013 - "SCIG treatment in CIDP is feasible, safe and effective, and seems an attractive alternative to IVIG."
07/01/2008 - "On the basis of available data, IVIg can be recommended as a first-line treatment option for GBS and CIDP. "
|3.||Autoimmune Diseases (Autoimmune Disease)
12/01/2014 - "Data from meta-analyses of heterogeneous placebo-controlled trials indicate that IVIg may be effective in secondary RM, but most trials to date have used immunomodulatory doses lower than those considered to be efficient in autoimmune disease. "
06/01/2005 - "The efficacy of IVIG has been established only in several autoimmune diseases; clinical reports of trials, series, and case reports indicate significant improvement in many more autoimmune diseases. "
12/01/1993 - "Results from the present study suggest a novel mechanism by which IVIg may be beneficial in human autoimmune diseases."
11/01/1994 - "The effect was evaluated of intravenous gammaglobulin (IVIg), a successful therapy in various autoimmune diseases, in relapsing-remitting MS patients treated for three years. "
03/01/1990 - "These results support the concept that IVIg may be beneficial in selected autoimmune diseases by modulating the function of the idiotypic network."
03/01/1998 - "The thrombocytopenia improved dramatically after IVIG therapy. "
10/01/2007 - "The therapeutic efficacy of IVIg in antibody-mediated thrombocytopenia was significantly reduced in presence of LPS. "
06/01/2015 - "Anti-CD44 is ineffective at inhibiting thrombocytopenia in B6;129S FcγRIIb-deficient mice but, like IVIG, is effective in splenectomized mice and FcγRIIb-deficient mice on the BALB/C and C57BL/6 background. "
05/01/2005 - "IVIg was first demonstrated to be effective in autoimmune disorders, two decades ago, in the treatment of acute immune thrombocytopenia. "
11/01/2002 - "The authors conclude that IVIG in the dose of 1 g/kg for 1-2 days is an effective treatment for NLE with severe thrombocytopenia especially when corticosteroid is contraindicated."
11/01/1995 - "We describe a group of patients with dermatomyositis, resistant to available therapies, whose muscle strength, skin changes, and muscle biopsies improved significantly during treatment with intravenous immune globulin. "
12/30/1993 - "High-dose intravenous immune globulin is a safe and effective treatment for refractory dermatomyositis."
01/01/2000 - "IVIG is effective in selected dermatomyositis patients. "
05/01/1996 - "In a double-blind, placebo-controlled study, using objective criteria for improvement, IVIG demonstrated moderate to dramatic improvement in 75% of the patients with dermatomyositis. "
09/01/2014 - "Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease."
|2.||Intravenous Immunoglobulins (IVIG)
|3.||Adrenal Cortex Hormones (Corticosteroids)
|4.||Immunoglobulin G (IgG)
|5.||Inosine Triphosphate (ITP)
|10.||Aspirin (Acetylsalicylic Acid)
|4.||Transplantation (Transplant Recipients)